Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2015 1
2017 1
2019 1
2020 3
2021 2
2022 2
2023 2
2024 4
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacoeconomic Review Report: Teduglutide (Revestive): (Shire Pharmaceuticals Ireland Limited): Indication: Treatment of adults and pediatric patients one year of age and above with short bowel syndrome who are dependent on parenteral support.
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Jan. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Jan. PMID: 33237681 Free Books & Documents. Review.
Teduglutide (Revestive) is indicated for use in adult and pediatric patients (one year of age and above) with short bowel syndrome (SBS) who are dependent on parenteral support (PS). Teduglutide is available as a 5 mg single-use vial, for subcutaneous injecti …
Teduglutide (Revestive) is indicated for use in adult and pediatric patients (one year of age and above) with short bowel synd …
Clinical Review Report: Teduglutide (Revestive): (Shire Pharmaceuticals Ireland Limited): Indication: Treatment of adults and pediatric patients one year of age and above with short bowel syndrome who are dependent on parenteral support.
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Jan. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Jan. PMID: 33237684 Free Books & Documents. Review.
The objective of the current CDR review was to perform a systematic review of the beneficial and harmful effects of teduglutide subcutaneous injection (Revestive) for the treatment of pediatric patients one year of age and above with Short bowel syndrome who are dep …
The objective of the current CDR review was to perform a systematic review of the beneficial and harmful effects of teduglutide subcu …
Tracking the physicochemical stability of teduglutide (Revestive ) clinical solutions over time in different storage containers.
Pérez-Robles R, Hermosilla J, Navas N, Clemente-Bautista S, Jiménez-Lozano I, Cabañas-Poy MJ, Ruiz-Travé J, Hernández-García MA, Cabeza J, Salmerón-García A. Pérez-Robles R, et al. J Pharm Biomed Anal. 2022 Nov 30;221:115064. doi: 10.1016/j.jpba.2022.115064. Epub 2022 Sep 17. J Pharm Biomed Anal. 2022. PMID: 36152491 Free article.
Teduglutide, the active ingredient of the medicine Revestive (5 mg), is a recombinant therapeutic peptide that mimics the effects of the endogenous glucagon-like peptide 2 (GLP-2). ...This study aims to carry out a long-term stability study that reproduces hospital …
Teduglutide, the active ingredient of the medicine Revestive (5 mg), is a recombinant therapeutic peptide that mimics the eff …
Teduglutide: a review of its use in the treatment of patients with short bowel syndrome.
Burness CB, McCormack PL. Burness CB, et al. Drugs. 2013 Jun;73(9):935-47. doi: 10.1007/s40265-013-0070-y. Drugs. 2013. PMID: 23729002 Review.
The recombinant analogue of human glucagon-like peptide-2 (GLP-2) teduglutide (Gattex( ), Revestive( )) is a novel therapy for short bowel syndrome (SBS). ...Subcutaneous teduglutide had an acceptable tolerability profile; the most frequently reported …
The recombinant analogue of human glucagon-like peptide-2 (GLP-2) teduglutide (Gattex( ), Revestive( )) is a novel ther …
CADTH Canadian Drug Expert Committee Recommendation: Teduglutide (Revestive - Shire Pharmaceuticals Ireland Limited): Indication: treatment of adults and pediatric patients 1 year of age and above with Short Bowel Syndrome who are dependent on parenteral support.
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Nov. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Nov. PMID: 33237677 Free Books & Documents. Review. No abstract available.
New approaches to the treatments of short bowel syndrome-associated intestinal failure.
Jeppesen PB. Jeppesen PB. Curr Opin Gastroenterol. 2014 Mar;30(2):182-8. doi: 10.1097/MOG.0000000000000046. Curr Opin Gastroenterol. 2014. PMID: 24406477 Review.
PURPOSE OF REVIEW: Teduglutide, a recombinant analog of human glucagon-like peptide 2, has recently been approved in the US and Europe (Gattex and Revestive, respectively) as the first targeted treatment of short bowel syndrome-associated intestinal failure ( …
PURPOSE OF REVIEW: Teduglutide, a recombinant analog of human glucagon-like peptide 2, has recently been approved in the US and Europ …
Teduglutide: A Review in Short Bowel Syndrome.
Kim ES, Keam SJ. Kim ES, et al. Drugs. 2017 Mar;77(3):345-352. doi: 10.1007/s40265-017-0703-7. Drugs. 2017. PMID: 28194723 Review.
Subcutaneous teduglutide (Revestive( )), a glucagon-like peptide-2 analogue that increases intestinal absorption, is approved in the EU for the treatment of short bowel syndrome (SBS) in patients aged 1 year who are stable following a period of postsurgical intesti …
Subcutaneous teduglutide (Revestive( )), a glucagon-like peptide-2 analogue that increases intestinal absorption, is approved …
Comprehensive physicochemical characterization of a peptide-based medicine: Teduglutide (Revestive ) structural description and stress testing.
Pérez-Robles R, Salmerón-García A, Hermosilla J, Torrente-López A, Clemente-Bautista S, Jiménez-Lozano I, Cabañas-Poy MJ, Cabeza J, Navas N. Pérez-Robles R, et al. Eur J Pharm Biopharm. 2023 Mar;184:103-115. doi: 10.1016/j.ejpb.2023.01.001. Epub 2023 Jan 18. Eur J Pharm Biopharm. 2023. PMID: 36669672 Free article.
Teduglutide (Revestive ) is a glucagon-like peptide-2 analogue used for the treatment of short bowel syndrome, a rare life-threatening condition in which the amount of functional gut is too short to enable proper absorption of nutrients and fluids. ...To the best of …
Teduglutide (Revestive ) is a glucagon-like peptide-2 analogue used for the treatment of short bowel syndrome, a rare life-thr …
Gut hormones in the treatment of short-bowel syndrome and intestinal failure.
Jeppesen PB. Jeppesen PB. Curr Opin Endocrinol Diabetes Obes. 2015 Feb;22(1):14-20. doi: 10.1097/MED.0000000000000120. Curr Opin Endocrinol Diabetes Obes. 2015. PMID: 25485516 Review.
PURPOSE OF REVIEW: The approval of teduglutide, a recombinant analog of human glucagon-like peptide (GLP) 2, by the US Food and Drug Administration (Gattex) and the European Medicines Agency (Revestive) has illustrated the potential of selected gut hormones a …
PURPOSE OF REVIEW: The approval of teduglutide, a recombinant analog of human glucagon-like peptide (GLP) 2, by the US Food and Drug …
Long-term teduglutide associated with improved response in pediatric short bowel syndrome-associated intestinal failure.
Wales PW, Hill S, Robinson I, Raphael BP, Matthews C, Cohran V, Carter B, Venick R, Kocoshis S. Wales PW, et al. J Pediatr Gastroenterol Nutr. 2024 Aug;79(2):290-300. doi: 10.1002/jpn3.12276. Epub 2024 Jun 14. J Pediatr Gastroenterol Nutr. 2024. PMID: 38873891
RESULTS: Overall, 85 patients were analyzed; 78 patients received teduglutide in the parent and/or LTE studies (any teduglutide [TED] group), while seven patients did not receive teduglutide in either the parent or LTE studies. ...CONCLUSIONS: In pediatric pa …
RESULTS: Overall, 85 patients were analyzed; 78 patients received teduglutide in the parent and/or LTE studies (any teduglutide …
17 results